Skip to content

Internet Chatter About December 20, 2012 FDA AdComm Negative Recommendation Of Hemispherx BioPharma’s Orphan Drug Ampligen (Rintatolimod)

December 21, 2012

       The Internet chatter about the December 20, 2012 FDA AdComm negative recommendation of Hemispherx BioPharma’s orphan drug Ampligen for Chronic Fatigue Syndrome (CFS) – there is currently no approved drugs for CFS  :

1)  Medscape December 21, 2012 article titled, “Rintatolimod for Chronic Fatigue Gets FDA No Vote”, identifies how the FDA Arthritis Advisory Committee voted :

     –  8 to 5 against the approval of drug for CFS

     –  4 to 9 against the adequacy of the data supporting the drug’s efficacy

     –  4 to 9 against the adequacy of the safety data

     –  8 to 5 in favor of drug’s safety profile overall, “given the severity of the illness and what some panel members felt was the absence of a serious safety signal”. 

2) December 21, 2012 Blog Post titled, “Panel rejects experimental chronic fatigue syndrome drug”

3)’s December 21, 2012 article titled, “Better Chance for Ampligen the 2nd Time ?”

4)  The Wall Street Journal December 20, 2012 article titled, “UPDATE: FDA Panel Rejects Hemispherx BioPharma’s Ampligen for Chronic Fatigue Syndrome”

5)  Fox 12 (KPTV) December 19, 2012 article titled, “Bronstein, Gewirtz & Grossman, LLC announces Investigation of Hemispherx BioPharma Inc”.

Copyright © 2012-2013, Orphan Druganaut Blog. All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: